Cncure
1 known investors
South Korean biotech developing bacteria-based cancer immunotherapy, molecular imaging and AI-driven drug screening.
Also known as CNCure Β· CNCure Biotech Β· μ¨μ€νμ΄
Investors Β· 1
Company profile
researched Aug 2026CNCure (CNCure Biotech) is a South Korean biotechnology company that combines drug development with imaging technology to build what it describes as an immuno-theranostic platform β approaches intended to support diagnosis and treatment simultaneously. Its stated core competencies span four areas: microbial-based cancer therapy (MCT), molecular imaging for clinical decision-making, radio-theranostics, and AI-driven screening of drug candidates.
The therapeutic side centers on engineered bacteria and microbiome-based platforms, marketed under the SAM designation, intended to target tumors and stimulate anticancer immune responses; company communications describe work on Salmonella-based anticancer agents. On the imaging and diagnostics side, the company lists molecular probe products including 18F-DMPY2 and 18F-FDS. AICureX is the company's AI-based drug screening capability, applied to predicting protein structures and identifying candidate compounds, and positioned as spanning drug design through patient treatment. The company's public site also lists science, pipeline, publications and patents sections.
Business model
The company positions itself as a platform-based developer of therapeutics and molecular imaging agents, with programs spanning microbial cancer therapy, radio-theranostics and AI-based drug screening, and pursues collaborations with external partners on drug development.
Latest developments
In July 2026 the company announced a partnership with Portrai to develop next-generation AI-based anticancer drugs, and Korean trade press profiled its Salmonella-based approach to starving tumors. In August 2026 the company delivered a keynote lecture on bacterial anticancer agents at the Gordon Research Conference.
βΈFull profile β market position, technology, go-to-market, geography, history
Market position
The company frames its distinguishing approach as integrating therapeutic development (microbial cancer therapy) with molecular imaging and AI-based screening in a single theranostic platform rather than pursuing these areas separately.
Technology
Technology areas include microbial-based cancer therapy (MCT) using engineered bacteria and microbiome platforms branded SAM, molecular imaging probes such as 18F-DMPY2 and 18F-FDS, radio-theranostics for combined diagnosis and treatment, and AICureX, an AI system for protein structure prediction and drug candidate extraction.
Go-to-market
Oncology drug development programs and clinicians using molecular imaging to assess and visualize therapeutic response.
Geography
Based in South Korea, operating a Korean-language corporate site and Korean media presence.
History
According to the company, CNCure Biotech has operated since 2019, led by specialists in bacterial engineering and molecular probe development. In 2026 the company reported a research collaboration with Portrai on AI-based anticancer drug development and a keynote presentation of its bacterial anticancer therapy research at the Gordon Research Conference.
Compiled by commissioned research from 4 cited public sources β announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed β not independently audited.
Timeline Β· 2
launches, deals, and filingsThe company presented its bacteria-based anticancer therapy research in a keynote lecture at the Gordon Research Conference (GRC).
CNCure and Portrai announced a joint effort to develop next-generation anticancer drugs using AI.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
βΈResearch sources Β· 4
primary sources listed
- CNCUREcncure.co.kr Β· web
4 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Cncure do?
- South Korean biotech developing bacteria-based cancer immunotherapy, molecular imaging and AI-driven drug screening.
- Who are Cncure's investors?
- Cncure's investors include Colopl Next.